ABOUT THIS EPISODE
In this special Crimes Against Innovation episode, host Nicola Hill hears two charges against the research system.
Professor Raj Chovatiya argues that the academic model is putting the brakes on innovation, squeezing creativity and collaboration. Meanwhile, Dr Joe Rastrick condemns the irreproducible published study, which can misdirect future research and waste resources.
Join the debate and decide which crime should carry the greater sentence.
Hosted on Acast. See acast.com/privacyhttps://acast.com/privacy for more information.
This podcast is produced and funded by UCB.
GL-OT-2600004 – May 2026
Hosted on Acast. See acast.com/privacy for more information.
English
United States
TRANSCRIPT 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
SEARCH PAST EPISODES
Search past episodes of Hypothesize That!.
OTHER EPISODES IN THIS PODCAST
In the darkened corridors of laboratories and the silent pages of medical journals, there are stories rarely spoken about—tales of brilliance that burned too bright, and ideas that strayed into catastrophe. This is—Crimes Against Innovation.
Laurence Woollard and Dr. Emma Lane debate two pre…
Are today’s clinical trials fit for the future of medicine, or are they holding innovation back?
In this episode, host Nicola Hill, is joined by Professor Maddie Parsons, Dean of Research Excellence Frameworks at King’s College London, and Dr Graham Price, Head of Global Clinical Developme…
Deep in the shadowy corridors of laboratories and the silent pages of medical journals, progress can falter, not for lack of brilliance, but because of the systems surrounding it. Ideas are delayed, discoveries are hidden, and bold thinking is quietly discouraged. This is Crimes Against Innovation.…
In this episode, we ask a defining question: will multi-specific therapies revolutionize how we treat complex diseases? Host Nicola Hill is joined by Dr Joe Rastrick (UCB) and Professor Raj Chovatiya (Rosalind Franklin University) to examine whether medicines engineered to target multiple pathways …
Disclaimer: The podcast and artwork embedded on this page are from UCB Biopharma, which is the property of its owner and not affiliated with or endorsed by Listen Notes, Inc.
EDIT
Thank you for helping to keep the podcast database up to date.
